Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts

6 analysts have shared their evaluations of Ionis Pharmaceuticals IONS during the recent three months, expressing a mix of bullish and bearish perspectives.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $65.0, a high estimate of $82.00, and a low estimate of $53.00. A 0.61% drop is evident in the current average compared to the previous average price target of $65.40.

Breaking Down Analyst Ratings: A Detailed Examination

The analysis of recent analyst actions sheds light on the perception of Ionis Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ionis Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.
• Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ionis Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Ionis Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Ionis Pharmaceuticals analyst ratings.

All You Need to Know About Ionis Pharmaceuticals

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ionis Pharmaceuticals: A Financial Overview

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Ionis Pharmaceuticals's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -8.45%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Ionis Pharmaceuticals's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -119.5%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Ionis Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -41.8%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Ionis Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.96%, the company may face hurdles in achieving optimal financial returns.

Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 4.87, caution is advised due to increased financial risk.

Analyst Ratings: Simplified

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.